Ascites analysis by a microfluidic chip allows tumor-cell profiling

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 51, 2013, Pages

  Peterson, Vanessa M ^a,b   Castro, Cesar M ^a,c   Chung, Jaehoon ^a   Miller, Nathan C ^a,b   Ullal, Adeeti V ^a,b   Castano, Maria D ^a   Penson, Richard T ^c   Lee, Hakho ^a   Birrer, Michael J ^c   Weissleder, Ralph ^a,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biomarkers; Molecular profiling; Personalized medicine

Indexed keywords

BIOLOGICAL MARKER; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CD24 ANTIGEN; CD45 ANTIGEN; EPITHELIAL CELL ADHESION MOLECULE; FOLR1 PROTEIN; MEMBRANE PROTEIN; TAG72 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; ASCITES; ASCITES TUMOR CELL; CELL COUNT; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; MICROCHIP ANALYSIS; MOLECULAR BIOLOGY; NANOFLUIDICS; OVARY CANCER; PERITONEAL FLUID; PRIORITY JOURNAL; PROTEIN PROCESSING; TREATMENT RESPONSE; TUMOR CELL;

EID: 84890840696     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1315370110     Document Type: Article

References (62)

1. Siegel R, Naishadham D, Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1): 11-30.
2. Na YJ, et al. (2009) Ovarian cancer: Markers of response. Int J Gynecol Cancer 19(Suppl 2):S21-S29.
3. Bast RCJ, Jr., Hennessy B, Mills GB (2009) The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer 9(6):415-428.
4. Lutz AM, et al. (2011) Early diagnosis of ovarian carcinoma: Is a solution in sight Radiology 259(2):329-345.
5. Zhang B, Cai FF, Zhong XY (2011) An overview of biomarkers for the ovarian cancer diagnosis. Eur J Obstet Gynecol Reprod Biol 158(2):119-123.
6. Nolen BM, Lokshin AE (2012) Protein biomarkers of ovarian cancer: The forest and the trees. Future Oncol 8(1):55-71.
7. Li AJ, et al. (2004) The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol 92(1):211-214.
8. Obermayr E, et al. (2013) Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance: A study of the OVCAD consortium. Gynecol Oncol 128(1):15-21.
9. Taylor DD, Gerçel-Taylor C (2005) Tumour-Derived exosomes and their role in cancerassociated T-Cell signalling defects. Br J Cancer 92(2):305-311.
10. Meirelles K, et al. (2012) Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc Natl Acad Sci USA 109(7):2358-2363.
11. Taylor DD, Gercel-Taylor C, Parker LP (2009) Patient-Derived tumor-Reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol 115(1):112-120.
12. Yip P, et al. (2011) Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers. PLoS ONE 6(12):e29533.
13. Kinde I, et al. (2013) Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers. Sci Transl Med 5(167):167ra4.
14. Buckanovich RJ, et al. (2007) Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 25(7):852-861.
15. Emmanuel C, et al.; Australian Ovarian Cancer Study Group (2011) Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis. PLoS ONE 6(3):e17617.
16. Oribabor JW, Ambrosio A, Castro CM, Birrer MJ (2012) Biotargets of Cancer in Current Clinical Practice, ed Bologna M (Springer/Humana Press, New York), pp 381-402.
17. Kipps E, Tan DS, Kaye SB (2013) Meeting the challenge of ascites in ovarian cancer: New avenues for therapy and research. Nat Rev Cancer 13(4):273-282.
18. Attanoos RL, Webb R, Dojcinov SD, Gibbs AR (2002) Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum. Histopathology 40(3): 237-244.
19. Comin CE, Saieva C, Messerini L (2007) h-Caldesmon, calretinin, estrogen receptor, and Ber-EP4: A useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. Am J Surg Pathol 31(8):1139-1148.
20. Laury AR, et al. (2010) PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol 34(5):627-635.
21. Ordóñez NG (1998) Role of immunohistochemistry in distinguishing epithelial peritoneal mesotheliomas from peritoneal and ovarian serous carcinomas. Am J Surg Pathol 22(10):1203-1214.
22. Ordóñez NG (2006) The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: A comparative study. Mod Pathol 19(1):34-48.
23. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609-615.
24. Elschenbroich S, et al. (2011) In-Depth proteomics of ovarian cancer ascites: Combining shotgun proteomics and selected reaction monitoring mass spectrometry. J Proteome Res 10(5):2286-2299.
25. Karst AM, Drapkin R (2011) The new face of ovarian cancer modeling: Better prospects for detection and treatment. F1000 Med Rep 3:22.
26. Scarberry KE, Dickerson EB, Zhang ZJ, Benigno BB, McDonald JF (2010) Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles. Nanomedicine 6(3):399-408.
27. Uhlen M, et al. (2010) Towards a knowledge-Based Human Protein Atlas. Nat Biotechnol 28(12):1248-1250.
28. LaRocca PJ, Rheinwald JG (1984) Coexpression of simple epithelial keratins and vimentin by human mesothelium and mesothelioma in vivo and in culture. Cancer Res 44(7):2991-2999.
29. Laury AR, et al. (2011) A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol 35(6):816-826.
30. Stussi G, et al. (2005) Isotype-Specific detection of ABO blood group antibodies using a novel flow cytometric method. Br J Haematol 130(6):954-963.
31. Ng PC, et al. (2004) Neutrophil CD64 is a sensitive diagnostic marker for early-Onset neonatal infection. Pediatr Res 56(5):796-803.
32. Armstrong DK, White AJ, Weil SC, Phillips M, Coleman RL (2013) Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-Sensitive ovarian cancer. Gynecol Oncol 129(3):452-458.
33. Teng L, Xie J, Teng L, Lee RJ (2012) Clinical translation of folate receptor-Targeted therapeutics. Expert Opin Drug Deliv 9(8):901-908.
34. Suh KS, et al. (2010) Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert Rev Mol Diagn 10(8):1069-1083.
35. Latifi A, et al. (2011) Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-Like profile. J Cell Biochem 112(10):2850-2864.
36. Kalluri R, Weinberg RA (2009) The basics of epithelial-Mesenchymal transition. J Clin Invest 119(6):1420-1428.
37. Voldman J, Gray ML, Schmidt MA (1999) Microfabrication in biology and medicine. Annu Rev Biomed Eng 1:401-425.
38. Xia Y, Whitesides GM (1998) Softlithographie. Angew Chem Int Ed 110:568-594.
39. Heitz F, et al. (2012) Bevacizumab in the treatment of ovarian cancer. Adv Ther 29(9): 723-735.
40. Carden CP, et al. (2012) The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Mol Cancer Ther 11(7):1609-1617.
41. Han L, et al. (2005) The clinical significance of EphA2 and Ephrin A-1 in epithelial ovarian carcinomas. Gynecol Oncol 99(2):278-286.
42. Landen CN, Kinch MS, Sood AK (2005) EphA2 as a target for ovarian cancer therapy. Expert Opin Ther Targets 9(6):1179-1187.
43. Lee JW, et al. (2009) EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst 101(17):1193-1205.
44. Huang CY, et al. (2006) Serum mesothelin in epithelial ovarian carcinoma: A new screening marker and prognostic factor. Anticancer Res 26(6C):4721-4728.
45. Bellone S, et al. (2009) Overexpression of epithelial cell adhesion molecule in primary, metastatic, and recurrent/chemotherapy-Resistant epithelial ovarian cancer: Implications for epithelial cell adhesion molecule-Specific immunotherapy. Int J Gynecol Cancer 19(5):860-866.
46. Ghazani AA, Castro CM, Gorbatov R, Lee H, Weissleder R (2012) Sensitive and direct detection of circulating tumor cells by multimarker ì-Nuclear magnetic resonance. Neoplasia 14(5):388-395.
47. Kristiansen G, et al. (2002) CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 161(4):1215-1221.
48. Richter CE, et al. (2010) High-Grade, chemotherapy-Resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Am J Obstet Gynecol 203(6):582.e1-582.e7.
49. Zecchini S, et al. (2011) The adhesion molecule NCAM promotes ovarian cancer progression via FGFR signalling. EMBO Mol Med 3(8):480-494.
50. Kachali C, Eltoum I, Horton D, Chhieng DC (2006) Use of mesothelin as a marker for mesothelial cells in cytologic specimens. Semin Diagn Pathol 23(1):20-24.
51. Kim JH, et al. (2009) Immunocytochemical panel for distinguishing between adenocarcinomas and reactive mesothelial cells in effusion cell blocks. Diagn Cytopathol 37(4):258-261.
52. Choi J-H, Choi K-C, Auersperg N, Leung PCK (2004) Overexpression of follicle-Stimulating hormone receptor activates oncogenic pathways in preneoplastic ovarian surface epithelial cells. J Clin Endocrinol Metab 89(11):5508-5516.
53. Ji Q, Liu PI, Chen PK, Aoyama C (2004) Follicle stimulating hormone-Induced growth promotion and gene expression profiles on ovarian surface epithelial cells. Int J Cancer 112(5):803-814.
54. Radu A, et al. (2010) Expression of follicle-Stimulating hormone receptor in tumor blood vessels. N Engl J Med 363(17):1621-1630.
55. Zheng W, et al. (2000) Ovarian epithelial tumor growth promotion by follicle-Stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol 76(1):80-88.
56. Haber DA, Gray NS, Baselga J (2011) The evolving war on cancer. Cell 145(1):19-24.
57. Zorn KK, et al. (2003) Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies. Clin Cancer Res 9(13):4811-4818.
58. Chung J, et al. (2013) Rare cell isolation and profiling on a hybrid magnetic/sizesorting chip. Biomicrofluidics 7:054107.
59. Chung J, et al. (2012) Microfluidic cell sorter (ìFCS) for on-Chip capture and analysis of single cells. Adv Healthc Mater 1(4):432-436.
60. Daniels VG, Wheater PR, Burkitt HG (1979) Functional Histology: A Text and Colour Atlas (Churchill Livingstone, Edinburgh).
61. Malkov VA, et al. (2009) Multiplexed measurements of gene signatures in different analytes using the Nanostring nCounter Assay System. BMC Res Notes 2:80.
62. Geiss GK, et al. (2008) Direct multiplexed measurement of gene expression with colorcoded probe pairs. Nat Biotechnol 26(3):317-325.